Pharming Group (PHAR)
(Delayed Data from NSDQ)
$8.00 USD
+0.58 (7.82%)
Updated Aug 14, 2024 02:22 PM ET
4-Sell of 5 4
C Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Pharming Group N.V. Sponsored ADR [PHAR]
Reports for Purchase
Showing records 21 - 38 ( 38 total )
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Priority Review For Leniolisib; Moving Toward Commercialization Backed by Robust Phase 2/3 Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
2Q22 Results; With Continued Ruconest Revenue Stream, Focus Now Is On Launch Preparation For Leniolisib
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Leniolisib Garners EMA Accelerated Assessment; MAA Filing By Year End
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
1Q22 Results; Ruconest Blocks and Tackles as Expected; Leniolisib Filings to FDA and EMA Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Leniolisib Is On a Roll With Regulatory Milestones in the U.K.; Expected Launch Anticipated in 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Happy Day Across the Pond; Leniolisib Pivotal Data Nail It; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Leniolisib?s Visibility Increases in Europe with Pediatric Component Ahead of Pivotal Data in 1Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Five-Year Contract Renewal Inked With Sanofi Helps Secure Ruconest Production and Significant Cost Savings
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
3Q21 Results; Ruconest Traction and Corporate Investments Continue; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Topline Data From Trials Evaluating Ruconest in COVID-19 Reported; Company Sponsored Study Reaches Primary Endpoint
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
2Q21 Results; The Ruconest Comeback Continues; New Patients and Product Demand Drive Continued Growth
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Strategic Agreement Bridges Ruconest to Untapped International Markets
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Long-Term Commitment to HAE Seeded with Orchard Partnership
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Leniolisib Pivotal Phase 2/3 Tops Off Patient Enrollment; Product Launch Anticipated in 4Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
1Q21 Results; Positive Trends Project Ruconest''s Growth Moving Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group N.V. Sponsored ADR
Industry: Medical - Biomedical and Genetics
2020 Results; Ruconest Traction Continues to Impress; Solid Cash Footing Bolsters Future
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J